Egy új, szubsztituált benzokinon tartalmú antimetasztatikus készítmény.

B. Szende, E. Rásó, M. Hídvégi, F. R. Tömösköziné, S. Paku, L. Prónai, J. Bocsi, K. Lapis

Research output: Article

10 Citations (Scopus)

Abstract

An orally applicable fermentation product of wheat germ containing 0.04% substituted benzoquinone (MSC) was invented by Hungarian chemists under the trade--name of AVEMAR. The following biological effects of this product were observed. Oral administration (3 g/kg body weight) of MSC enhances blastic transformation of splenic lymphocytes of mice. The same treatment shortens the survival time of skin grafts in co-isogenic mouse skin transplantation model, which points to immune-reconstructive effect of MSC. Highly significant anti-metastatic effect of MSC was observed in three metastasis models (3LL-HH, B16, HCR-25). The antimetastatic activity of MSC--besides the immune reconstitution--may also due to the cell-adhesion inhibitory, cell proliferation inhibitory, apoptosis-enhancing and antioxidant effects, which were also observed in our in vitro experiments. Based on the biological effects of MSC--which is non-toxic, according to subacute toxicology studies--this product may be used as an adjuvant in the therapy of malignant neoplasia and other diseases caused by or following immunedeprivation.

Original languageHungarian
Pages (from-to)2893-2897
Number of pages5
JournalOrvosi Hetilap
Volume139
Issue number48
Publication statusPublished - nov. 29 1998

Fingerprint

Skin Transplantation
Lymphocyte Activation
Cell Adhesion
Toxicology
Triticum
Fermentation
Names
Oral Administration
Antioxidants
Body Weight
Cell Proliferation
Apoptosis
Neoplasm Metastasis
Transplants
Skin
Therapeutics
Neoplasms
benzoquinone
In Vitro Techniques

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egy új, szubsztituált benzokinon tartalmú antimetasztatikus készítmény. / Szende, B.; Rásó, E.; Hídvégi, M.; Tömösköziné, F. R.; Paku, S.; Prónai, L.; Bocsi, J.; Lapis, K.

In: Orvosi Hetilap, Vol. 139, No. 48, 29.11.1998, p. 2893-2897.

Research output: Article

@article{7d948af4e3c6413089b39047596205c2,
title = "Egy {\'u}j, szubsztitu{\'a}lt benzokinon tartalm{\'u} antimetasztatikus k{\'e}sz{\'i}tm{\'e}ny.",
abstract = "An orally applicable fermentation product of wheat germ containing 0.04{\%} substituted benzoquinone (MSC) was invented by Hungarian chemists under the trade--name of AVEMAR. The following biological effects of this product were observed. Oral administration (3 g/kg body weight) of MSC enhances blastic transformation of splenic lymphocytes of mice. The same treatment shortens the survival time of skin grafts in co-isogenic mouse skin transplantation model, which points to immune-reconstructive effect of MSC. Highly significant anti-metastatic effect of MSC was observed in three metastasis models (3LL-HH, B16, HCR-25). The antimetastatic activity of MSC--besides the immune reconstitution--may also due to the cell-adhesion inhibitory, cell proliferation inhibitory, apoptosis-enhancing and antioxidant effects, which were also observed in our in vitro experiments. Based on the biological effects of MSC--which is non-toxic, according to subacute toxicology studies--this product may be used as an adjuvant in the therapy of malignant neoplasia and other diseases caused by or following immunedeprivation.",
author = "B. Szende and E. R{\'a}s{\'o} and M. H{\'i}dv{\'e}gi and T{\"o}m{\"o}sk{\"o}zin{\'e}, {F. R.} and S. Paku and L. Pr{\'o}nai and J. Bocsi and K. Lapis",
year = "1998",
month = "11",
day = "29",
language = "Hungarian",
volume = "139",
pages = "2893--2897",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "48",

}

TY - JOUR

T1 - Egy új, szubsztituált benzokinon tartalmú antimetasztatikus készítmény.

AU - Szende, B.

AU - Rásó, E.

AU - Hídvégi, M.

AU - Tömösköziné, F. R.

AU - Paku, S.

AU - Prónai, L.

AU - Bocsi, J.

AU - Lapis, K.

PY - 1998/11/29

Y1 - 1998/11/29

N2 - An orally applicable fermentation product of wheat germ containing 0.04% substituted benzoquinone (MSC) was invented by Hungarian chemists under the trade--name of AVEMAR. The following biological effects of this product were observed. Oral administration (3 g/kg body weight) of MSC enhances blastic transformation of splenic lymphocytes of mice. The same treatment shortens the survival time of skin grafts in co-isogenic mouse skin transplantation model, which points to immune-reconstructive effect of MSC. Highly significant anti-metastatic effect of MSC was observed in three metastasis models (3LL-HH, B16, HCR-25). The antimetastatic activity of MSC--besides the immune reconstitution--may also due to the cell-adhesion inhibitory, cell proliferation inhibitory, apoptosis-enhancing and antioxidant effects, which were also observed in our in vitro experiments. Based on the biological effects of MSC--which is non-toxic, according to subacute toxicology studies--this product may be used as an adjuvant in the therapy of malignant neoplasia and other diseases caused by or following immunedeprivation.

AB - An orally applicable fermentation product of wheat germ containing 0.04% substituted benzoquinone (MSC) was invented by Hungarian chemists under the trade--name of AVEMAR. The following biological effects of this product were observed. Oral administration (3 g/kg body weight) of MSC enhances blastic transformation of splenic lymphocytes of mice. The same treatment shortens the survival time of skin grafts in co-isogenic mouse skin transplantation model, which points to immune-reconstructive effect of MSC. Highly significant anti-metastatic effect of MSC was observed in three metastasis models (3LL-HH, B16, HCR-25). The antimetastatic activity of MSC--besides the immune reconstitution--may also due to the cell-adhesion inhibitory, cell proliferation inhibitory, apoptosis-enhancing and antioxidant effects, which were also observed in our in vitro experiments. Based on the biological effects of MSC--which is non-toxic, according to subacute toxicology studies--this product may be used as an adjuvant in the therapy of malignant neoplasia and other diseases caused by or following immunedeprivation.

UR - http://www.scopus.com/inward/record.url?scp=0032578934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032578934&partnerID=8YFLogxK

M3 - Article

C2 - 9868904

AN - SCOPUS:0032578934

VL - 139

SP - 2893

EP - 2897

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 48

ER -